Persistent HIV-1-specific cellular responses despite prolonged therapeutic viral suppression

V Appay, P Hansasuta, J Sutton, RD Schrier, JK Wong… - Aids, 2002 - journals.lww.com
V Appay, P Hansasuta, J Sutton, RD Schrier, JK Wong, M Furtado, DV Havlir, SM Wolinsky
Aids, 2002journals.lww.com
Design Antiretroviral therapy (ART) currently represents the best way to avert the lethal
consequences of chronic persistent HIV-1 infection. It leads to significant reductions of
plasma viremia, often to undetectable levels, but it can also be linked with the reduction and
disappearance of detectable HIV-specific CD8 T-cell responses. Results Here we describe a
group of patients in whom ongoing replication of HIV, particularly transcription of Nef mRNA
species, was detected despite prolonged and clinically successful antiretroviral treatment …
Abstract
Design
Antiretroviral therapy (ART) currently represents the best way to avert the lethal consequences of chronic persistent HIV-1 infection. It leads to significant reductions of plasma viremia, often to undetectable levels, but it can also be linked with the reduction and disappearance of detectable HIV-specific CD8 T-cell responses.
Results
Here we describe a group of patients in whom ongoing replication of HIV, particularly transcription of Nef mRNA species, was detected despite prolonged and clinically successful antiretroviral treatment. Modest, but significant, numbers of HIV-specific CD8 T cells and CD4 T-cell responses were found in these subjects, with the strongest responses directed towards Nef epitopes. Detailed phenotypic analysis of the HIV-specific CD8 cells demonstrated low perforin levels and persistent expression of CD27, a phenotype associated with incomplete differentiation of cytotoxic T lymphocytes (CTL).
Conclusion
This immature CTL phenotype has been described previously in association with chronic HIV disease, but its continued persistence is surprising in the setting of prolonged viral suppression on therapy and the presence of HIV-specific CD4 cell activity.
Lippincott Williams & Wilkins